Floatz logo

ALLOGENEIC HUMAN UMBILICAL CORD BLOOD

Relapsed T-Cell Lymphoma

Masonic Cancer Center, University of MinnesotaCell therapyPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the Relapsed T-Cell Lymphoma cohort.

Asset / SponsorPhaseRating
Fludarabine
GC Cell Corporation
Phase 2BBB
Monomethyl Fumarate
Masonic Cancer Center, University of Minnesota
Phase 2BB
FILGRASTIM
Sichuan University
Phase 3BB
Rapamycin
Masonic Cancer Center, University of Minnesota
Phase 2B
Equine Atg
Masonic Cancer Center, University of Minnesota
Phase 2B

View all 9 →

Same molecule, other indications

ALLOGENEIC HUMAN UMBILICAL CORD BLOOD is also rated in:

acute lymphoblastic leukemiaDormant
B
Indicative ·
61 / 100
View asset →
acute myeloid leukemiaDormant
B
Indicative ·
59 / 100
View asset →
myelodysplastic syndromeDormant
B
Indicative ·
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →